You are here

Home » Content

Angiotensin I Converting Enzyme Gene Polymorphism in Type 2 Diabetes Mellitus with Nephropathy in Saudi Population

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2017

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Background and aim: Diabetic Nephropathy (DN) is a major microvascular complication in Type 2 diabetes mellitus (T2DM). Several environmental and genetic factors play a pivotal role in the development and pathogenesis of DN. The angiotensin-converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism is one of the various genetic factors associated with DN. This study was undertaken to assess the frequency and distribution of ACE I/D polymorphism in T2DM with and without nephropathy patients and controls. Materials and methods: We conducted a case-control study. In a population of 61 patients suffering from T2DM without nephropathy and 61 patients T2DM with nephropathy along with the 52 age matched controls in Saudi populations. ACE I/D polymorphism was detected by PCR amplification using allele specific primers and some biochemical and behavioral markers were monitored. Chi-square and multiple logistic regression analyses were done to determine the odds ratio for development of nephropathy. Results: The observed genotype frequencies of II, ID and DD in T2DM with nephropathy were 8.2%, 34.4% and 57.4%, in T2DM without nephropathy 16.4%, 44.2% and 39.4%, in control 30.8%, 48.1%, 21.1% respectively. The DD genotype of the T2DM with nephropathy group was higher than the T2DM without nephropathy patients (OR=2.075, 95% CI: 1.008-4.272, p=0.047). Conclusion: The study illustrated that significant association was observed between the D allele, DD genotype of the ACE gene polymorphism and T2DM with nephropathy in Al- Quwayiyah region of Saudi Arabia. We suggest potential and new multi-property of ACE inhibitors therapy for the prevention or delay of progression of nephropathy.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-angiotensin-i-converting-enzyme-gene-polymorphism-type-2-diabetes-mellitus-nephropathy-saudi-population.pdf
  • 10
12
20
  • English

REFERENCES

References: 

[1] Nazir, Nyla, et al. “Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis
involved in different biochemical pathways.” BMC Medical Genetics Vol. 15, No. 1, 2014, p. 103.
[2] Matough, Fatmah A., et al. “The role of oxidative stress and antioxidants in diabetic complications.” Sultan Qaboos
University Medical Journal Vol. 12, No. 1, 2012, p. 5.
[3] Yin, Hui Qing. “Relationship between oxidant/antioxidant markers and severity of microalbuminuria in the early
stage of nephropathy in type 2 diabetic patients.” Experimental Diabetes Research 2013.
[4] Zhang, Dongying, et al. “Effects of MCF2L2, ADIPOQ and SOX2 genetic polymorphisms on the development
of nephropathy in type 1 Diabetes Mellitus.” BMC Medical Genetics Vol. 11 No. 1, 2010, p. 116.
[5] Xu, Zhong-Gao, et al. “Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of
arachidonate metabolism in obese Zucker rat kidney.” Circulation Vol. 111, No. 15, 2005, pp. 1962-69.
[6] Jeffers, Barrett W., et al. “Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes
mellitus and its relationship with diabetic nephropathy.” Kidney International Vol. 52, No. 2, 1997, pp. 473-77.
[7] Naresh, V.V.S., et al. “Angiotensin converting enzyme gene polymorphism in type 2 diabetics with nephropathy.”
Indian Journal of Nephrology Vol. 20, No. 2, 2010, p. 119.
Samir Abdulkarim Alharbi, et al. Int J Med Res Health Sci 2017, 6(10): 12-20
19
[8] Paz-Pacheco, Elizabeth, et al. “Angiotensin I-converting enzyme gene polymorphism and diabetic nephropathy
in Filipino Type 2 diabetes mellitus patients.” Journal of the ASEAN Federation of Endocrine Societies Vol. 27,
No. 1, 2014, p. 87.
[9] Saddick, Salina Y. “Angiotensin converting enzyme gene polymorphism studies: A case-control study.” Saudi
Journal of Biological Sciences Vol. 22, No. 3, 2015, pp. 327-31.
[10] Chmaisse, Hania Nakkash, et al. “A study on the association between angiotensin-I converting enzyme I/D dimorphism
and type-2 diabetes mellitus.” Saudi Journal of Kidney Diseases and Transplantation Vol. 20, No. 6,
2009, p. 1038.
[11] Khan, M. Kaleemullah, et al. “ACE I/D gene polymorphism in diabetic nephropathy: Clinical implications.” Journal
of Medical & Allied Sciences Vol. 1, No. 1, 2011, p. 42.
[12] Golmohamadi, T., et al. “Association of angiotensin converting enzyme (ACE) gene polymorphism and diabetic
nephropathy.” Iranian Journal of Public Health Vol. 35, No. 3, 2006, pp. 14-21.
[13] World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and
intermediate hyperglycemia: Report of a WHO/IDF consultation. World Health Organization. 2006.
[14] Trinder, P. “Blood sugar estimation by GOD-POD method.” Annals of Clinical Biochemistry Vol. 6, 1969, pp.
24-27.
[15] Karl, J. “Development and standardization of a new immunoturbidimetric HbA_<1c> assay.” Klinicheskaia
Laboratornaia Diagnostika Vol. 39, 1993, pp. 991-96.
[16] Rigat, Brigitte, et al. “PCR detection of the insertion/deletion polymorphism of the human angiotensin converting
enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).” Nucleic Acids Research Vol. 20, No. 6, 1992, p. 1433.
[17] Tanaka, Chihiro, et al. “An alternative fast and convenient genotyping method for the screening of angiotensin
converting enzyme gene polymorphisms.” Hypertension Research Vol. 26, No. 4, 2003, pp. 301-06.
[18] Domingos, Ana Carolina Bonini, et al. “Angiotensin converting enzyme polymorphism in type 2 diabetes mellitus.”
Biomarkers and Genomic Medicine Vol. 6, No. 3, 2014, pp. 99-104.
[19] Lee, Wen-Chin, Chau-Jong Wang, and Huei-Jane Lee. “Antioxidants in decelerating diabetic nephropathy.” Type
1 Diabetes. InTech, 2013.
[20] Van Ittersum, Frans J., et al. “Genetic polymorphisms of the renin–angiotensin system and complications of
insulin-dependent diabetes mellitus.” Nephrology Dialysis Transplantation Vol. 15, No. 7, 2000, pp. 1000-07.
[21] Yousef, Hala Mosad, et al. “Association of angiotensin converting enzyme gene polymorphism and diabetic
nephropathy in type 2 diabetes mellitus in Sharkia Governorate.” Zagazig University Medical Journal Vol. 20,
No. 3, 2015.
[22] Tarnow, Lise, Christian Gluud, and Hans-Henrik Parving. “Diabetic nephropathy and the insertion/deletion
polymorphism of the angiotensin-converting enzyme gene.” Nephrology, dialysis, transplantation: official publication
of the European Dialysis and Transplant Association-European Renal Association Vol. 13, No. 5, 1998,
pp. 1125-30.
[23] Marre, Michel, et al. “Relationships between angiotensin I converting enzyme gene polymorphism, plasma
levels, and diabetic retinal and renal complications.” Diabetes Vol. 43, No. 3, 1994, pp. 384-88.
[24] Pasha, M. A. Qadar, et al. “Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism
in Indian populations of different ethnic origins.” Journal of Biosciences Vol. 27, No. 1, 2002, pp. 67-70.
[25] Solini, Anna, et al. “The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions
in type 2 diabetes.” Diabetes Vol. 51, No. 1, 2002, pp. 251-55.
[26] Ergen, H. Arzu, et al. “Angiotensin-I converting enzyme gene polymorphism in Turkish type 2 diabetic patients.”
Experimental & Molecular Medicine Vol. 36, No. 4, 2004, p. 345.
[27] Nakhjavani, Manouchehr, and Ladan Dibai. “Association of angiotensin-converting enzyme gene insertion/
deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.” Archives of Iranian
Medicine Vol. 11, No. 1, 2008, pp. 3-9.
Samir Abdulkarim Alharbi, et al. Int J Med Res Health Sci 2017, 6(10): 12-20
20
[28] Daimon, Makoto, et al. “The D allele of the angiotensin-converting enzyme insertion/deletion (I/D) polymorphism
is a risk factor for type 2 diabetes in a population-based Japanese sample.” Endocrine Journal Vol. 50, No.
4, 2003, pp. 393-98.
[29] Van Valkengoed, Irene GM, et al. “The angiotensin converting enzyme insertion/deletion polymorphism and
differences in fasting plasma glucose in Hindustani Surinamese, African Surinamese and ethnic Dutch: the population-
based SUNSET-study.” Diabetes Research and Clinical Practice Vol. 81, No. 1, 2008, pp. e12-e14.
[30] Sagnella, Giuseppe A., et al. “A population study of ethnic variations in the angiotensin‐converting enzyme I/D
polymorphism: relationships with gender, hypertension and impaired glucose metabolism.” Journal of Hypertension
Vol. 17, No. 5, 1999, pp. 657-64.
[31] Stephens, Jeffrey W., et al. “The D allele of the ACE I/D common gene variant is associated with Type 2 diabetes
mellitus in Caucasian subjects.” Molecular Genetics and Metabolism Vol. 84, No. 1, 2005, pp. 83-89.
[32] Haque, S.F., et al. “ACE Insertion/Deletion gene polymorphism and genomic sequence in Diabetic nephropathy.”
International Journal of Diabetes and Metabolism Vol. 18, 2010, pp. 114-18.
[33] Grzeszczak, Władysław, et al. “Angiotensin I-converting enzyme gene polymorphisms: relationship to nephropathy
in patients with non-insulin dependent diabetes mellitus.” Journal of the American Society of Nephrology
Vol. 9, No. 9, 1998, pp. 1664-69.
[34] Schmidt, Susanne, et al. “Association of ACE gene polymorphism and diabetic nephropathy?” Kidney International
Vol. 47, No. 4, 1995, pp. 1176-81.
[35] Liao L., et al. “Relationship between serum ACE activity and diabetic retinopathy in patients with type II diabetes.”
Hunan Yike Dayue Xue Bao Vol. 24, No. 3, 1999, pp. 263-66.
[36] Arfa, Imen, et al. “Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism
and diabetic nephropathy in Tunisian type 2 diabetic patients.” Journal of the Renin-Angiotensin-Aldosterone
System Vol. 9, No. 1, 2008, pp. 32-36.
[37] Moleda, P., et al. “Relationship between I/D polymorphism of angiotensin I converting enzyme gene and microvascular
complications in type 2 diabetic patients.” Przeglad lekarski Vol. 64, No. 3, 2007, pp. 134-39.
[38] Yoshida, Hiroaki, et al. “Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes
mellitus.” Kidney International Vol. 50, No. 2, 1996, pp. 657-64.
[39] Nikzamir, Abdol Rahim, et al. “Angiotensin converting enzyme gene polymorphism in Iranian patients with type
2 diabetes.” Iranian Journal of Immunology Vol. 3, No. 1, 2006, pp. 23-29.
[40] Wang, Yuying, et al. “The association of ACE gene polymorphism with diabetic kidney disease and renoprotective
efficacy of valsartan.” Journal of the Renin-Angiotensin-Aldosterone System Vol. 17, No. 3, 2016, p.
1470320316666749.
[41] El-Bazz, Walaa F., et al. Detection of angiotensin converting enzyme gene polymorphism in Egyptian patients
with diabetic nephropathy. Australian Journal of Basic and Applied Sciences. Vol. 5. 2011, pp. 244-51.
[42] Kumar, Ajay, Kapil Mohindru, and P. K. Sehajpal. “Angiotensin-I converting enzyme polymorphism and diabetic
nephropathy in North India.” International Journal of Human Genetics Vol. 5, No. 4, 2005, p. 279.
[43] Prasad, Pushplata, et al. “Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS
gene polymorphisms.” BMC Medical Genetics Vol. 7, No. 1, 2006, p. 42.
[44] Long, David A., et al. “How does angiotensin II cause renal injury?” Hypertension Vol. 43, No. 4, 2004, pp.
722-23.
[45] Parving, Hans-Henrik, et al. “ACE gene polymorphism and losartan treatment in type 2 diabetic patients with
nephropathy.” Journal of the American Society of Nephrology Vol. 19, No. 4, 2008, pp. 771-79.

Thank you for copying data from http://www.arastirmax.com